Science libraryBiblioteka nauke

Research profile 03Istraživački profil 03

CJC-1295 / IpamorelinCJC-1295 / Ipamorelin

Two growth-hormone-axis research compounds. Small human studies address the components, not a standardized body-recomposition combination.Dve istraživačke supstance koje deluju na osu hormona rasta. Male studije kod ljudi proučavaju komponente, a ne standardizovanu kombinaciju za rekompoziciju tela.

Fat loss & body recompositionGubitak masti i rekompozicija telaComponents studied separatelyKomponente proučavane odvojenoNo dosing guidanceBez smernica za doziranje
Evidence profileProfil dokazaCJC-1295 / IpamorelinCJC-1295 / Ipamorelin
Evidence levelNivo dokazaComponents studied separatelyKomponente proučavane odvojeno
Editorial ruleUredničko praviloFindings and limits shown togetherNalazi i ograničenja prikazani zajedno

A research category organizes reading. It is not a promise of an individual outcome.Istraživačka kategorija organizuje čitanje. Ona nije obećanje individualnog ishoda.

Molecular classMolekulska klasaGHRH analogue + ghrelin-receptor agonistAnalog GHRH + agonista grelinskog receptora
Research statusStatus istraživanjaEarly human pharmacology; combination efficacy has not been establishedRana farmakologija kod ljudi; efikasnost kombinacije nije utvrđena
Human evidenceDokazi kod ljudiSmall component studies; no established CJC/IPA body-recomposition trialMale studije komponenti; nema utvrđene studije CJC/IPA za rekompoziciju tela
Profile reviewedProfil pregledan7 September 20267. septembar 2026.

Plain-language overviewJasan pregled

Define the molecules before reading the claim.Definišite molekule pre tumačenja tvrdnje.

CJC-1295 is a growth-hormone-releasing-hormone analogue. Published healthy-adult studies evaluated the long-acting form with a drug-affinity-complex (DAC) modification. The phrase “CJC-1295 without DAC” is often used imprecisely for modified GRF(1–29); these are not interchangeable identities.CJC-1295 je analog hormona koji oslobađa hormon rasta. Objavljene studije kod zdravih odraslih ispitivale su dugodelujući oblik sa modifikacijom kompleksa afiniteta prema leku (DAC). Izraz „CJC-1295 bez DAC-a“ često se neprecizno koristi za modifikovani GRF(1–29); to nisu zamenljivi identiteti.

Ipamorelin is a ghrelin-receptor agonist and growth-hormone secretagogue. Early healthy-volunteer pharmacology and a later postoperative-ileus trial do not establish a body-recomposition benefit for a CJC/ipamorelin mixture.Ipamorelin je agonista grelinskog receptora i sekretagog hormona rasta. Rana farmakologija kod zdravih dobrovoljaca i kasnija studija postoperativnog ileusa ne utvrđuju korist mešavine CJC/ipamorelin za rekompoziciju tela.

Read the educational boundaryPročitajte edukativnu granicu

Selected primary sourcesOdabrani primarni izvori

Open the study.
Check the model.Otvorite studiju.
Proverite model.

These are curated starting points, not an exhaustive bibliography. Live PubMed and ClinicalTrials.gov searches below expose the broader and changing record.Ovo su odabrane polazne tačke, a ne iscrpna bibliografija. Pretrage uživo na PubMed-u i ClinicalTrials.gov u nastavku prikazuju širi zapis koji se menja.

2006
Randomized human pharmacologyRandomizovana farmakologija kod ljudi

Prolonged stimulation of growth hormone and IGF-I by CJC-1295Produžena stimulacija hormona rasta i IGF-I pomoću CJC-1295

Journal of Clinical Endocrinology & Metabolism

Randomized, placebo-controlled healthy-adult studies examined CJC-1295 pharmacokinetics and hormone responses, not body-recomposition outcomes.Randomizovane, placebom kontrolisane studije kod zdravih odraslih ispitivale su farmakokinetiku CJC-1295 i hormonske odgovore, a ne ishode rekompozicije tela.

2007
Human pulsatility studyStudija pulsiranja kod ljudi

CJC-1295 preserves growth-hormone pulsatility in healthy adultsCJC-1295 čuva pulsiranje hormona rasta kod zdravih odraslih

Journal of Clinical Endocrinology & Metabolism

A small study characterized growth-hormone secretion after CJC-1295 with DAC. It did not test a CJC/ipamorelin blend.Mala studija opisala je lučenje hormona rasta nakon CJC-1295 sa DAC-om. Nije ispitivala mešavinu CJC/ipamorelin.

1999
Ipamorelin first-in-humanPrva primena ipamorelina kod ljudi

Pharmacokinetics and pharmacodynamics of ipamorelin in healthy volunteersFarmakokinetika i farmakodinamika ipamorelina kod zdravih dobrovoljaca

Journal of Clinical Endocrinology & Metabolism

A dose-escalation study documented pharmacology and growth-hormone response in healthy volunteers.Studija povećanja doze dokumentovala je farmakologiju i odgovor hormona rasta kod zdravih dobrovoljaca.

2015
Randomized proof-of-conceptRandomizovani dokaz koncepta

Ipamorelin for postoperative ileusIpamorelin za postoperativni ileus

International Journal of Colorectal Disease

The registered clinical setting was postoperative ileus. The trial reported no significant difference from placebo in its efficacy endpoints.Registrovani klinički kontekst bio je postoperativni ileus. Studija nije prijavila značajnu razliku u odnosu na placebo u ishodima efikasnosti.

Living literatureŽiva literatura

Continue with current databases.Nastavite u aktuelnim bazama podataka.

Search results can change as papers and trial records are added or updated.Rezultati pretrage mogu se menjati kako se radovi i zapisi studija dodaju ili ažuriraju.

PubMed ClinicalTrials.gov
Reasonable interpretationRazumno tumačenje

What the evidence supports.Šta dokazi podržavaju.

  • CJC-1295 with DAC increased growth hormone and IGF-1 measures in small healthy-adult studies.CJC-1295 sa DAC-om povećao je mere hormona rasta i IGF-1 u malim studijama kod zdravih odraslih.
  • Ipamorelin produced measurable growth-hormone responses in an early dose-escalation study.Ipamorelin je proizveo merljiv odgovor hormona rasta u ranoj studiji povećanja doze.
  • The components have distinct identities and must be evaluated separately.Komponente imaju različite identitete i moraju se procenjivati odvojeno.
Critical boundaryKritična granica

What it does not establish.Šta se time ne dokazuje.

  • Clinically meaningful fat loss, muscle gain or body recomposition from the named combination.Klinički značajan gubitak masti, dobitak mišića ili rekompoziciju tela od navedene kombinacije.
  • Equivalence between CJC-1295 with DAC and products described as “without DAC.”Ekvivalentnost između CJC-1295 sa DAC-om i proizvoda opisanih kao „bez DAC-a“.
  • Long-term safety or the quality of any mixed vial.Dugoročnu bezbednost ili kvalitet bilo koje mešane bočice.

Future verificationBuduća verifikacija

The literature explains the target. The report examines the sample.Literatura objašnjava cilj. Izveštaj ispituje uzorak.

A mixed-vial record must name the exact CJC sequence and DAC status, identify both components, quantify each component independently where the method permits, and avoid presenting one combined purity number as proof of both identities.Zapis mešane bočice mora navesti tačnu CJC sekvencu i DAC status, identifikovati obe komponente, kvantifikovati svaku komponentu zasebno kada metoda to omogućava i izbegavati predstavljanje jednog zbirnog broja čistoće kao dokaza oba identiteta.

Understand the test fieldsRazumite polja testiranja
Related guidePovezani vodič

Storage claims need formulation-specific evidence too.Tvrdnje o čuvanju takođe zahtevaju dokaze specifične za formulaciju.

Storage & handlingČuvanje i rukovanje